Cannabis Stocks Rally Toward Best Weekly Performance in Two Years

Cannabis stocks are experiencing their strongest weekly rally in nearly two years, with major operators and MSOs posting double-digit gains as investor sentiment shifts dramatically. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed over 12% this week, while individual names like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) have posted even steeper advances. This marks a stark reversal from the sector's prolonged bear market that has persisted since the initial euphoria of 2021.

The rally comes as institutional investors reassess cannabis valuations following months of overselling. Many MSOs now trade at enterprise value-to-sales ratios below 2x, levels that appear increasingly attractive given their cash generation capabilities and dominant market positions in key states. Curaleaf, for instance, generates over $300 million in quarterly revenue yet trades at a fraction of traditional retail multiples, creating compelling risk-adjusted opportunities for value-oriented funds.

Federal rescheduling momentum continues building beneath the surface, with the DEA's review process advancing through administrative channels. While timeline uncertainty persists, the probability of cannabis moving from Schedule I to Schedule III has increased meaningfully over recent months. This shift would eliminate the punitive 280E tax burden that currently restricts MSO profitability, potentially unlocking billions in additional cash flow across the sector.

Operational fundamentals among top-tier operators remain robust despite stock price volatility. Same-store sales growth has stabilized across most mature markets, while new state launches in Ohio, Minnesota, and other emerging jurisdictions provide fresh revenue catalysts. The industry's transition from growth-at-any-cost to disciplined expansion has strengthened balance sheets and improved unit economics, setting the stage for sustained profitability as regulatory headwinds diminish.

This week's performance suggests institutional capital may finally be rotating back into cannabis after nearly three years of systematic outflows. Trading volumes have spiked across major names, indicating genuine buying interest rather than short covering. However, the sector's notorious volatility means investors should expect continued price swings as the market digests evolving regulatory developments and quarterly earnings results over the coming months.